EP0154434A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Human transforming growth factor and precursor or fragment thereof, cells, DNA, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods
Assignee: Genentech Inc
•
Filing: 1985-02-15
•
Granted: —
•
Expires: 2005-02-15
Abstract
Abstract Recombinant DNA technology is used to produce the transforming growth factor-a (TGF-a) precursor and its fragments. TGF-a precursor and its fragments, including particularly mature TGF-a, and optionally in combination with human transforming growth factor-β, has utility for example in the therapeutic treatment of human beings for bone diseases and to accelerate wound healing. In addition, TGF-a is useful as an adjuvant for cell culture so as to reduce requirements for serum in the culture media (thereby resulting in purification advantages), and to stimulate or enhance cell growth in cell culture. Also, preparation of large quantities of the TGF-a precursor and its fragments enables the preparation of reagents for the assay of the TGF-a precursor and its fragments in body fluids for the diagnosis of neoplastic or other diseases.
Inventors
- 👤 Rik Michel Andre Derynck
- 👤 David Vannorman Goeddel
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 11:10
CPC Classifications
A; A61; A61L; A61L15/00; A61L15/16; A61L15/22; A61L15/32; C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; C07K16/00; C07K16/18; C07K16/22; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/57575; G01N33/5758; G01N33/57585; G01N33/74; A61K; A61K38/00; G01N2333/00; G01N2333/435; G01N2333/475; G01N2333/495; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/828; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
20 words
A bandage impregnated with a product comprising human mature TGF-a, TGF-aC, TGF-aN or TGF-amC essentially free of other human proteins.
Claim 2
Dependent Claim
20 words
A bandage impregnated with a product comprising human mature TGF-a, TGF-aC, TGF-aN or TGF-amC essentially free of other human proteins.
Claim 3
Dependent Claim
15 words
A composition comprising precursor TGF-a or a fragment thereof produced by heterologous recombinant host cells.
Claim 4
Dependent Claim
15 words
A composition comprising precursor TGF-a or a fragment thereof produced by heterologous recombinant host cells.
Claim 5
Dependent Claim
16 words
A composition of claim 2 wherein the precursor of TGF-a or its fragment is a mutant.
Claim 6
Dependent Claim
38 words
A composition of claim 2 conjugated to a heterologous polypeptide which is heterologous to the organism from which was obtained the recombinant DNA encoding the precursor TGF-a or its fragment, the heterologous polypeptide being a microbial signal sequence.
Claim 7
Dependent Claim
24 words
A composition of claim 2 wherein the precursor TGF-a or its fragment is human and additionally comprising a predetermined amount of a human protein.
Claim 8
Dependent Claim
12 words
A composition of claim 2 which is labelled with a detectable moiety.
Claim 9
Dependent Claim
23 words
A composition of claim 2 which further comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of precursor TGF-a or its fragment.
Claim 10
Dependent Claim
17 words
A composition of claim 7 which is sterile and which further comprises a predetermined amount of TGF-S.
Claim 11
Dependent Claim
11 words
A composition of claim 8 for topical application to a wound.
Claim 12
Dependent Claim
24 words
A DNA sequence encoding precursor TGF-a or a fragment thereof, provided that when the fragment is mature TGF-a then the mature TGF-a is human.
Claim 13
Dependent Claim
24 words
A DNA sequence encoding precursor TGF-a or a fragment thereof, provided that when the fragment is mature TGF-a then the mature TGF-a is human.
Claim 14
Dependent Claim
13 words
The DNA sequence of claim 10 ligated to DNA encoding a heterologous polypeptide.
Claim 15
Dependent Claim
13 words
A replicable vector comprising the DNA sequence of claim 10 or claim 11.
Claim 16
Dependent Claim
9 words
A cell transformed with the vector of claim 12.
Claim 17
Independent Claim
74 words
A method for producing a polypeptide comprising TGF-a precursor or a fragment thereof, comprising: (a) preparing an expression vector capable of acting in concert with a host cell to express a DNA sequence encoding said polypeptide; (b) transforming said host cell with the expression vector to obtain a recombinant host cell; (c) culturing the recombinant host cell under conditions for expression of the product; and (d) recovering the product from the host cell culture.
Claim 18
Independent Claim
74 words
A method for producing a polypeptide comprising TGF-a precursor or a fragment thereof, comprising: (a) preparing an expression vector capable of acting in concert with a host cell to express a DNA sequence encoding said polypeptide; (b) transforming said host cell with the expression vector to obtain a recombinant host cell; (c) culturing the recombinant host cell under conditions for expression of the product; and (d) recovering the product from the host cell culture.
Claim 19
Dependent Claim
17 words
A diagnostic method comprising assaying a body tissue or fluid for the presence of TGF-amC or TGF-aC.
Claim 20
Dependent Claim
17 words
A diagnostic method comprising assaying a body tissue or fluid for the presence of TGF-amC or TGF-aC.
Claim 21
Dependent Claim
80 words
A diagnostic method for determining TGF-amC comprising: (a) contacting a body fluid sample with an antibody capable of binding the TGF-aC domain of TGF-αmC; (b) contacting the body fluid sample with an antibody capable of binding the mature TGF-a domain of TGF-amC; (c) labelling the antibody of parts (a) or (b) with a detectable moiety; (d) insolubilizing the antibody which is not labelled; (e) separating the soluble and insoluble phases; and (f) measuring the distribution of label between the phases.
Claim 22
Dependent Claim
80 words
A diagnostic method for determining TGF-amC comprising: (a) contacting a body fluid sample with an antibody capable of binding the TGF-aC domain of TGF-αmC; (b) contacting the body fluid sample with an antibody capable of binding the mature TGF-a domain of TGF-amC; (c) labelling the antibody of parts (a) or (b) with a detectable moiety; (d) insolubilizing the antibody which is not labelled; (e) separating the soluble and insoluble phases; and (f) measuring the distribution of label between the phases.
Claim 23
Dependent Claim
13 words
An antibody raised against a predetermined amino acid sequence within a PRTGF-a species.
Claim 24
Dependent Claim
13 words
An antibody raised against a predetermined amino acid sequence within a PRTGF-a species.
Claim 25
Dependent Claim
11 words
An antibody according to claim 17 for administration to an animal.
Claim 26
Dependent Claim
29 words
A sterile therapeutic composition comprising a pharmaceutically acceptable carrier and a therapeutically effective dose of a TGF-a binding agent for inhibiting the activation of cell surface receptors by TGF-a.
Claim 27
Dependent Claim
29 words
A sterile therapeutic composition comprising a pharmaceutically acceptable carrier and a therapeutically effective dose of a TGF-a binding agent for inhibiting the activation of cell surface receptors by TGF-a.
References Cited (Backward Citations)
EP0128733A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.